David J Reeves1, Teresa C Kam2, Susan H Storey3. 1. Assistant Professor, College of Pharmacy and Health Sciences, Butler University. 2. Pharmacy Practice Resident, Department of Pharmacy, St. Vincent Hospital, Indianapolis, Indiana. 3. Oncology Clinical Nurse Specialist, Department of Clinical Nurse Specialists, St. Vincent Hospital, Indianapolis, Indiana. Corresponding author: David J Reeves, PharmD, BCOP, Assistant Professor, College of Pharmacy and Health Sciences, Butler University, 4600 Sunset Avenue, Indianapolis, IN 46208; phone: 317-338-2537; fax: 317-338-6761; e-mail: dreeves@butler.edu.
Abstract
PURPOSE: To characterize and identify trends in current practices for ordering, handling, dispensing, administering, and disposing of oral antineoplastics. METHODS: An electronic survey was designed and sent to pharmacists and nurses via professional society listservs. RESULTS: One hundred and twenty-three practitioners responded to the survey. Of those responding, 76% described having an official policy regarding the handling of oral antineoplastics. Prescribing was limited to attending physicians or oncologists the majority of the time (42% and 98%, respectively), with 11% accepting telephone orders for oral antineoplastics. Personal protective equipment was required by many of the respondents; 70% required gloves be worn. Patient contact precautions were utilized by 79% of practitioners, of which 81% followed similar precautions for targeted therapies. Compounding was required to be performed in a biological safety cabinet by 88% of respondents, and 83% required decontamination of supplies and equipment after exposure to oral antineoplastics. CONCLUSION: Although practices varied slightly, the majority of respondents follow available guidance when handling oral antineoplastics.
PURPOSE: To characterize and identify trends in current practices for ordering, handling, dispensing, administering, and disposing of oral antineoplastics. METHODS: An electronic survey was designed and sent to pharmacists and nurses via professional society listservs. RESULTS: One hundred and twenty-three practitioners responded to the survey. Of those responding, 76% described having an official policy regarding the handling of oral antineoplastics. Prescribing was limited to attending physicians or oncologists the majority of the time (42% and 98%, respectively), with 11% accepting telephone orders for oral antineoplastics. Personal protective equipment was required by many of the respondents; 70% required gloves be worn. Patient contact precautions were utilized by 79% of practitioners, of which 81% followed similar precautions for targeted therapies. Compounding was required to be performed in a biological safety cabinet by 88% of respondents, and 83% required decontamination of supplies and equipment after exposure to oral antineoplastics. CONCLUSION: Although practices varied slightly, the majority of respondents follow available guidance when handling oral antineoplastics.
Authors: Saul N Weingart; Jonathan Flug; Daniela Brouillard; Laurinda Morway; Ann Partridge; Sylvia Bartel; Lawrence N Shulman; Maureen Connor Journal: BMJ Date: 2007-01-12
Authors: Saul N Weingart; Elizabeth Brown; Peter B Bach; Kirby Eng; Shirley A Johnson; Timothy M Kuzel; Terry S Langbaum; R Donald Leedy; Raymond J Muller; Lee N Newcomer; Susan O'Brien; Denise Reinke; Mark Rubino; Leonard Saltz; Ronald S Walters Journal: J Natl Compr Canc Netw Date: 2008-03 Impact factor: 11.908
Authors: Susan Goodin; Niesha Griffith; Beth Chen; Karen Chuk; Mikael Daouphars; Christian Doreau; Rinku A Patel; Rowena Schwartz; Maria José Tamés; Robert Terkola; Barbara Vadnais; Debbie Wright; Klaus Meier Journal: J Oncol Pract Date: 2011-01 Impact factor: 3.840